Waystar Considers Sale Amid Falling Market Value, Sources Reveal

Waystar, a prominent healthcare software company known for its payment management technologies, is reportedly exploring strategic options, including a potential sale. This move comes just two years after the company went public on the New York Stock Exchange. Insiders familiar with the situation have indicated that Waystar has engaged investment bank Evercore to assist with the process, though it remains in its early stages.

The company, headquartered in Lehi, Utah, and Louisville, Kentucky, has seen its market capitalization drop to approximately $4.8 billion. This decline follows a 24% decrease in share price this year, part of a broader downturn in the software sector. The potential sale could test investor interest in software firms amid market volatility.

Shift in Strategic Positioning

Waystar has attempted to distinguish itself from traditional healthcare services by focusing on software solutions that automate and streamline administrative tasks. This strategy was intended to attract higher valuations associated with technology companies. Initially, investors were optimistic, driving the company's stock from $20 to a peak of $45 in 2025. However, concerns about the impact of artificial intelligence on software companies have since put pressure on Waystar's stock, according to a July report by Morgan Stanley analysts.

The company was formed through the merger of Zirmed and Navicure in 2017 and went public in 2024. Its major investors include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, with EQT holding the largest stake at 13%. CPPIB and BlackRock Institutional Trust Company hold 10% and 8% stakes, respectively.

Uncertain Future

While the exploration of a sale indicates a strategic pivot, insiders caution that plans could change, and a sale might not occur. The current evaluation process aims to determine whether there is renewed investor appetite for software companies, despite recent market challenges.

Neither Waystar nor its advisors at Evercore have commented on the situation. Similarly, representatives from EQT, CPPIB, and BlackRock have declined or not responded to requests for comment.

This potential sale underscores the ongoing challenges and shifts within the healthcare technology sector, as companies navigate market dynamics and investor expectations.